 |
JHP Pharmaceuticals Introduces a Dantrium® IV
(dantrolene sodium for injection), rapidly mixing at 20 seconds
PARSIPPANY, NJ SEPTEMBER 28 2009
JHP Pharmaceuticals, LLC (“JHP”) announced today that it had developed, and received approval by the FDA for Dantrium® IV (dantrolene sodium for injection), a rapidly mixing product. Dantrium® IV now reconstitutes in approximately 20 seconds, which is 4 times faster than before, saving valuable time and effort during a malignant hyperthermia (MH) emergency.
Dantrium® IV, the rapidly mixing product, has the following essential benefits
Reconstitutes in approximately 20 seconds with noticeably less vigorous shaking required to complete the reconstitution process
Easier and faster introduction of diluent into the Dantrium® IV vial
JHP has also introduced two new features in the Dantrium® IV vial; an easy-to-open flip-off vial cap and an easy-to-identify red vial cap and red vial label.
Additional Press Releases
 |
JHP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
Webpage
|
PDF Format |
|
|
JHP Pharmaceuticals & SpePharm complete
purchase
of Dantrium® (dantrolene sodium)
Webpage
|
PDF Format |
|
|
King Pharmaceuticals To Sell Rochester,
Michigan Manufacturing Facility To JHP
Pharmaceuticals
Webpage
|
PDF Format |
|
|
|
 |
|
